A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection
In the absence of an effective and safe vaccine against HIV-1, the administration of broadly neutralizing antibodies (bNAbs) represents a logical alternative approach to prevent virus transmission. Here, we introduced two mutations encoding amino acid substitutions (M428L and N434S, collectively ref...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989326/ https://www.ncbi.nlm.nih.gov/pubmed/29662199 http://dx.doi.org/10.1038/s41591-018-0001-2 |
_version_ | 1783329436744024064 |
---|---|
author | Gautam, Rajeev Nishimura, Yoshiaki Gaughan, Natalie Gazumyan, Anna Schoofs, Till Buckler-White, Alicia Seaman, Michael S. Swihart, Bruce J. Follmann, Dean A. Nussenzweig, Michel C. Martin, Malcolm A. |
author_facet | Gautam, Rajeev Nishimura, Yoshiaki Gaughan, Natalie Gazumyan, Anna Schoofs, Till Buckler-White, Alicia Seaman, Michael S. Swihart, Bruce J. Follmann, Dean A. Nussenzweig, Michel C. Martin, Malcolm A. |
author_sort | Gautam, Rajeev |
collection | PubMed |
description | In the absence of an effective and safe vaccine against HIV-1, the administration of broadly neutralizing antibodies (bNAbs) represents a logical alternative approach to prevent virus transmission. Here, we introduced two mutations encoding amino acid substitutions (M428L and N434S, collectively referred to as ‘LS’) into the genes encoding the crystallizable fragment domains of the highly potent HIV-specific 3BNC117 and 10-1074 bNAbs to increase their half-lives and evaluated their efficacy in blocking infection following repeated low-dose mucosal challenges of rhesus macaques (Macaca mulatta) with the tier 2 SHIV(AD8-EO). A single intravenous infusion of 10-1074-LS monoclonal antibodies markedly delayed virus acquisition for 18 to 37 weeks (median, 27 weeks), whereas the protective effect of the 3BNC117-LS bNAb was more modest (provided protection for 11–23 weeks; median, 17 weeks). Serum concentrations of the 10-1074-LS monoclonal antibody gradually declined and became undetectable in all recipients between weeks 26 and 41, whereas the 3BNC117-LS bNAb exhibited a shorter half-life. To model immunoprophylaxis against genetically diverse and/or neutralization-resistant HIV-1 strains, a combination of the 3BNC117-LS plus 10-1074-LS monoclonal antibodies was injected into macaques via the more clinically relevant subcutaneous route. Even though the administered mixture contained an amount of each bNAb that was nearly threefold less than the quantity of the single monoclonal antibody in the intravenous injections, the monoclonal antibody combination still protected macaques for a median of 20 weeks. The extended period of protection observed in macaques for the 3BNC117-LS plus 10-1074-LS combination could translate into an effective semiannual or annual immunoprophylaxis regimen for preventing HIV-1 infections in humans. |
format | Online Article Text |
id | pubmed-5989326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-59893262018-06-06 A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection Gautam, Rajeev Nishimura, Yoshiaki Gaughan, Natalie Gazumyan, Anna Schoofs, Till Buckler-White, Alicia Seaman, Michael S. Swihart, Bruce J. Follmann, Dean A. Nussenzweig, Michel C. Martin, Malcolm A. Nat Med Article In the absence of an effective and safe vaccine against HIV-1, the administration of broadly neutralizing antibodies (bNAbs) represents a logical alternative approach to prevent virus transmission. Here, we introduced two mutations encoding amino acid substitutions (M428L and N434S, collectively referred to as ‘LS’) into the genes encoding the crystallizable fragment domains of the highly potent HIV-specific 3BNC117 and 10-1074 bNAbs to increase their half-lives and evaluated their efficacy in blocking infection following repeated low-dose mucosal challenges of rhesus macaques (Macaca mulatta) with the tier 2 SHIV(AD8-EO). A single intravenous infusion of 10-1074-LS monoclonal antibodies markedly delayed virus acquisition for 18 to 37 weeks (median, 27 weeks), whereas the protective effect of the 3BNC117-LS bNAb was more modest (provided protection for 11–23 weeks; median, 17 weeks). Serum concentrations of the 10-1074-LS monoclonal antibody gradually declined and became undetectable in all recipients between weeks 26 and 41, whereas the 3BNC117-LS bNAb exhibited a shorter half-life. To model immunoprophylaxis against genetically diverse and/or neutralization-resistant HIV-1 strains, a combination of the 3BNC117-LS plus 10-1074-LS monoclonal antibodies was injected into macaques via the more clinically relevant subcutaneous route. Even though the administered mixture contained an amount of each bNAb that was nearly threefold less than the quantity of the single monoclonal antibody in the intravenous injections, the monoclonal antibody combination still protected macaques for a median of 20 weeks. The extended period of protection observed in macaques for the 3BNC117-LS plus 10-1074-LS combination could translate into an effective semiannual or annual immunoprophylaxis regimen for preventing HIV-1 infections in humans. Nature Publishing Group US 2018-04-16 2018 /pmc/articles/PMC5989326/ /pubmed/29662199 http://dx.doi.org/10.1038/s41591-018-0001-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Gautam, Rajeev Nishimura, Yoshiaki Gaughan, Natalie Gazumyan, Anna Schoofs, Till Buckler-White, Alicia Seaman, Michael S. Swihart, Bruce J. Follmann, Dean A. Nussenzweig, Michel C. Martin, Malcolm A. A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection |
title | A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection |
title_full | A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection |
title_fullStr | A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection |
title_full_unstemmed | A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection |
title_short | A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection |
title_sort | single injection of crystallizable fragment domain–modified antibodies elicits durable protection from shiv infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989326/ https://www.ncbi.nlm.nih.gov/pubmed/29662199 http://dx.doi.org/10.1038/s41591-018-0001-2 |
work_keys_str_mv | AT gautamrajeev asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT nishimurayoshiaki asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT gaughannatalie asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT gazumyananna asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT schoofstill asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT bucklerwhitealicia asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT seamanmichaels asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT swihartbrucej asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT follmanndeana asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT nussenzweigmichelc asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT martinmalcolma asingleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT gautamrajeev singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT nishimurayoshiaki singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT gaughannatalie singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT gazumyananna singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT schoofstill singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT bucklerwhitealicia singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT seamanmichaels singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT swihartbrucej singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT follmanndeana singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT nussenzweigmichelc singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection AT martinmalcolma singleinjectionofcrystallizablefragmentdomainmodifiedantibodieselicitsdurableprotectionfromshivinfection |